Coronavirus vaccine - Zydus Cadila
Latest Information Update: 29 Jul 2020
At a glance
- Originator Zydus Cadila
- Class Attenuated vaccines; COVID-19 vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
Development Overview
Introduction
Coronavirus vaccine is a recombinant, live attenuated, measles virus vectored against COVID-19 is being developed by Zydus Cadila, for the prevention of COVID-2019 infections using Etna Biotech's measles reverse genetics technology. The recombinant measles virus (rMV) produced by reverse genetics would express codon-optimised proteins of the coronavirus and intends to induce long-term specific neutralising antibodies to protect against the infection. Preclinical development is underway in Europe and India.
Zydus Cadila is looking for partners for development of vaccine for COVID-2019 infections (Zydus Cadila website, February 2020).
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Attenuated vaccines, COVID-19 vaccines, Synthetic vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07 (Vaccines)
-
EPhMRA code
J7A9 (Other specified single component)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | Prevention | Preclinical | Europe, India | Parenteral / unspecified | Zydus Cadila | 20 Apr 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Zydus Cadila | Originator | India |
| Zydus Cadila | Owner | India |
| Etna Biotech | Technology Provider | Italy |
Licensing Availability
| Licensing Organisation | Available Indication | Available Phase | Region | Date |
|---|---|---|---|---|
| Zydus Cadila | - | Unspecified | - | 24 Feb 2020 |
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 30 Jun 2020 | Trial Update | Zydus Cadila plans clinical development in COVID-2019 infections (Prevention) (Parenteral) by second quarter of 2020 [1] | 24 Apr 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 04 Jul 2020 | Trial Update | Zydus Cadila plans a phase I/II trial in Healthy volunteers in India (Intradermal) (CTRI/2020/07/026352) Updated 29 Jul 2020 |
| 20 Apr 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019 infections (Prevention) in Europe (Parenteral) [1] Updated 24 Apr 2020 |
| 20 Apr 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019 infections (Prevention) in India (Parenteral) [1] Updated 24 Apr 2020 |
| 20 Apr 2020 | Trial Update | Zydus Cadila plans clinical development in COVID-2019 infections (Prevention) (Parenteral) by second quarter of 2020 [1] Updated 24 Apr 2020 |
| 24 Feb 2020 | Licensing Status | Coronavirus vaccine - Zydus Cadila is available for licensing as of 24 Feb 2020. https://www.zyduscadila.com/ (Zydus Cadila Pipeline, February 2020) Updated 05 Mar 2020 |
| 15 Feb 2020 | Phase Change | Early research in COVID-2019-infections in India, Europe (Prevention) (Parenteral) Updated 05 Mar 2020 |
References
-
Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG